CANADA: LIFE-CYCLE INSIGHTS 

IPD’s Canadian subscription offers read-through and improved forecasting for litigation events happening around the world, featuring:

Easy-to-use launch

tracking schedules

​

In-the-courtroom coverage with real-time email updates

ƒPersonalized consults with local analysts to get answers to questions like these ƒ

Dispute tracking

ƒAll-inclusive weekly

Watch List ƒ

​

Complete drug tear sheets with product information, indications, and

loss-of-exclusivity

scenario analyses

LOGIN  |  REGISTER TO LISTEN

"Like the USFDA, Health Canada grants certain regulatory exclusivity for branded drug products, but there are some differences. For example, in Canada, there's no orphan drug exclusivity, or new product exclusivity for branded drug products. Health Canada only grants regulatory exclusivity for the first approval of a novel active pharmaceutical ingredient, whereas in the United States, new chemical entity exclusivity means that generic manufacturers cannot file an application to market a generic drug product until four years after the brand gets approval, and generics cannot be approved themselves until at least seven and a half years after brand approval."

PODCAST